Agios Pharmaceuticals Inc (STU:8AP)
€ 34.2 -3 (-8.06%) Market Cap: 1.93 Bil Enterprise Value: 1.03 Bil PE Ratio: 3.01 PB Ratio: 1.20 GF Score: 50/100

Agios Pharmaceuticals Inc at RBC Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 07:40PM GMT
Release Date Price: €44.5 (+0.52%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

All right. Thank you so much for joining our next session here. My name is Kennen MacKay. I'm one of the Senior Biotechnology Analysts here at RBC, and it's my great pleasure to have with us on this next session, Agios. And from Agios, we have Dr. Jackie Fouse, Agios' Chief Executive Officer. Jackie, thanks so much for joining.

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Happy to be here, being late is my fault you can tell them that. So...

Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

I'll shoulder the blame of the technical difficulties. Thank you, again, for joining. Thank you again for doing a video. Before we dive in with some fireside chat questions Agios is really at sort of a pivotal point in terms of the company's history now with really some potentially major rare disease programs very close on the horizon. Maybe you can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot